We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
---|---|---|---|---|---|
Antisoma | LSE:ASM | London | Ordinary Share | GB0055696032 | ORD 1P |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.00 | 0.00% | 1.325 | - | 0.00 | 00:00:00 |
Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
---|---|---|---|---|---|
0 | 0 | N/A | 0 |
Date | Subject | Author | Discuss |
---|---|---|---|
02/3/2011 11:07 | Now we have the ORA guy on board,I think things will happen soon | balcony | |
01/3/2011 15:03 | Crikey talk about falling on your sword, they are cutting the board, CEO and Finance officer gone, big savings. | freddie ferret | |
01/3/2011 14:30 | No way. Short traders closing some positions. | clubman | |
01/3/2011 10:38 | All buys more news coming I reckon | davenic | |
01/3/2011 10:14 | Resignation of Edwards and Dodds | jsbach123 | |
01/3/2011 10:06 | JSB: what good news? | sonicx | |
01/3/2011 08:25 | Looks like good news to me. | jsbach123 | |
28/2/2011 14:39 | Interesting! No thank you's or cermony or the usual bs? Have some of the bigger shs started the cost cutting with gusto? Something afoot? | cumnor | |
26/2/2011 17:20 | Ye and look at the state of them | bluechef | |
26/2/2011 16:27 | Filbert that is less than OXBs John Dawson who gets over £600,000 a year. | freddie ferret | |
26/2/2011 14:24 | The management also had vast over inflated salaries. Glyn Edwards got 357,000 pounds (approx $571,000) in 2010. Ridiculous. | filbert3 | |
25/2/2011 09:44 | I have been in this since 2003, dont tell me it has a decisive management team. It has been milked left right and centre. For a small bio tech it is substanially over staffed and has been poorly guided.There have been many opportunities to pull money out of this stock but on paper it had real potential, not any more mate. | bluechef | |
24/2/2011 21:17 | No FF I'm not interested in the performance or otherwise of any other biotech - it is this one that seems as though its likely (well read certain) to have lost me cash - I'm just hoping that the loss will be less than at first I feared if they are reasonably smart. What other biotechs do is up to them. | jsbach123 | |
24/2/2011 16:59 | Compare the management of this with some other biotechs which do their best to keep the truth shrouded in mystery and confusion. | freddie ferret | |
24/2/2011 16:43 | Well said bluechef! | jsbach123 | |
24/2/2011 09:39 | Decisive management? Course it is mate. | bluechef | |
23/2/2011 15:44 | We wait and see. It's a decisive management, they will say when they have something to talk about. | freddie ferret | |
23/2/2011 15:41 | Ff, would do you think they are trying to do, have something reverse in here? | joeblogg2 | |
23/2/2011 15:37 | Buys ahead of sells big time on both LSE and PLUS. | freddie ferret | |
22/2/2011 17:19 | The management in their last RNS said they were going to be issueing another shortly re slimming the board. Knowing what I know about this management the longer we wait the more exciting the RNS is likely to be, and probably about more than just slimming the board. 3p tomorrow? | freddie ferret | |
22/2/2011 14:10 | well - well done to those buying at the lows. I considered it and didnt have any spare cash anyway, but thought it would rise less than it has. | the_doctor | |
21/2/2011 17:25 | Creeping up. | freddie ferret | |
18/2/2011 15:24 | I think this company is on bid alert and will be taken out at a price that will give us all a good profit if you bought a few weeks ago soon after the bad news | sagem | |
18/2/2011 11:28 | cumnor Yep, not a bad idea, merge, shelve their own pipeline rather than flog off the ip for peanuts, slash workforce/management promising tiddlers, leaving plenty of cash to take the new products forward and then IF things develop positively in the future, they would possibly have opportunities to re-investigate the old pipeline once more. | kmjs |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions